Home・Akcijų sąrašas・Kura Oncology Inc

Kura Oncology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

9.51 3.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.49

Max

9.58

Pagrindiniai rodikliai
By Trading Economics
Pajamos	7.7M -73M
Pardavimai	929K 18M
Pelnas, tenkantis vienai akcijai	-0.828
Pelno marža	-401.495
Darbuotojai	260
EBITDA	13M -73M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+193.73% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-28M 816M
Ankstesnė atidarymo kaina	6.48
Ankstesnė uždarymo kaina	9.51

Naujienos nuotaikos

By Acuity

37%

63%

111 / 340 reitingas Healthcare

Kura Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-07 23:36; UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

2026-08-06 21:02; UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

2026-08-05 19:26; UTC

News

Kura Oncology Inc shares are lower today amid ongoing market volatility. The company will report second-quarter 2026 results after the market close on August 12.

2026-08-04 19:36; UTC

Kura Oncology Inc shares are higher today, continuing an upward trend since Monday. Broader market reactions follow a decline in U.S. core factory orders.

2026-08-03 23:01; UTC

Kura Oncology Inc. shares are higher in after-market trading, reflecting notable gains since Monday's close, despite no specific news to explain the increase.

2026-07-31 21:01; UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable rise since Friday's close despite remaining below the 20-day moving average.

2026-07-30 19:49; UTC

Kura Oncology Inc shares are higher Thursday, continuing a recent upward trend despite no specific news. The stock has rebounded from earlier session lows.

2026-07-29 19:22; UTC

Macro Event

Kura Oncology shares are lower, extending a six-session decline amid market volatility following the Federal Reserve's interest rate decision.

2026-07-28 20:03; UTC

Event

Kura Oncology shares are lower despite positive Phase 1a trial results for darlifarnib plus cabozantinib, reflecting broader market pressures.

2026-07-27 20:07; UTC

Social Media

News

Event

Kura Oncology shares are lower as the company reported Phase 1a results from its FIT-001 trial, showing a 33% to 50% response rate.

2026-07-22 22:01; UTC

Kura Oncology Inc. shares are lower in after-market trading, reflecting unusual volatility amid broader market fluctuations from rising crude oil prices and geopolitical tensions.

2026-07-21 19:36; UTC

Kura Oncology shares are higher Tuesday, amid positive market sentiment despite an earlier pullback. The stock remains below its 20-day moving average.

2026-07-20 18:36; UTC

Kura Oncology shares are lower today, pulling back from earlier gains amid a broader market decline linked to rising Treasury yields and geopolitical tensions.

Akcijų palyginimas

Kainos pokytis

Kura Oncology Inc Prognozė

Kainos tikslas

By TipRanks

193.73% į viršų

12 mėnesių prognozė

Vidutinis 28.11 USD 193.73%

Aukščiausias 40 USD

Žemiausias 15 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Kura Oncology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Kura Oncology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

111 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.